THE CLEAR STUDY: A PROSPECTIVE, RANDOMIZED, CONTROLLED, OPEN-LABEL MULTICENTRE 6-MONTH STUDY COMPARING THE EFFICACY AND SAFETY OF A 5-DAY 3-G DAILY MMF LOADING DOSE VERSUS STANDARD 2-G MMF DAILY DOSING IN RENAL TRANSPLANT RECIPIENTS

被引：0

作者：

Kiberd, Bryce A. ^{[1
]}

Gourishankar, Sita ^{[2
]}

Houde, Isabelle ^{[3
]}

Keown, Paul ^{[4
]}

Landsberg, David ^{[5
]}

Cardella, Carl ^{[6
]}

Barama, Azemi ^{[7
]}

Dandavino, Raymond ^{[8
]}

Shoker, Ahmed ^{[9
]}

Pirc, Lidia ^{[10
]}

Wrobel, Michelle ^{[10
]}

机构：

[1] QEII Hlth Sci Ctr, Halifax, NS, Canada

[2] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada

[3] Hotel Dieu Quebec, Quebec City, PQ, Canada

[4] Vancouver Hosp, Vancouver, BC, Canada

[5] St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada

[6] UHN Toronto Gen, Toronto, ON, Canada

[7] CHUM Hop Notre Dame, Montreal, PQ, Canada

[8] Hop Maison Neuve Rosemont, Montreal, PQ, Canada

[9] St Pauls Hosp, Saskatoon, SK, Canada

[10] F Hoffmann La Roche & Co Ltd, Mississauga, ON, Canada

来源：

TRANSPLANT INTERNATIONAL | 2009年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

引用

页码：120 / 120

页数：1

共 5 条

[1] The CLEAR Study: A Prospective, Randomized, Controlled, Open-Label, Multicentre 6-Month Study Comparing the Efficacy and Safety of a 5-Day 3-g Daily Mycophenolate Mofetil (MMF) Loading Dose Versus Standard 2-g MMF Daily Dosing in Renal Allograft Transplant Recipients.
Gourishankar, Sita
Houde, Isabelle
Keown, Paul
Wrobel, Michelle
Kiberd, Bryce
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 219 - 219
[2] The CLEAR Study: A 5-day, 3-g Loading Dose of Mycophenolate Mofetil versus Standard 2-g Dosing in Renal Transplantation
Gourishankar, Sita
Houde, Isabelle
Keown, Paul A.
Landsberg, David
Cardella, Carl J.
Barama, Azemi A.
Dandavino, Raymond
Shoker, Ahmed
Pirc, Lidia
Wrobel, Michelle M.
Kiberd, Bryce A.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (07): : 1282 - 1289
[3] Renal function evaluation after half dose reduction of Neoral® in combination with CellCept® in renal transplant patients with altered renal function:: Preleminary 2 year safety and efficacy results of the MMF -: Reference study:: A randomised, open, multicentre, prospective, controlled study.
Kessler, M
Frimat, L
Charpentier, B
Durrbach, A
Noel, C
Pruvot, FR
Glotz, D
Fraoui, R
Cassuto-Viguier, E
Durand, D
Cointault, O
Sraer, JD
Akposso, K
Bourbigot, B
Moal, MC
Moulin, B
Caillard, S
Lang, P
Fruchaud, G
Chalopin, JM
Ducloux, D
Pouteil-Noble, C
Bergougnoux, L
Biguenet, S
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 285 - 285
[4] A 12-month, multicenter, randomized, adaptive design, open-label study to evaluate the benefit of C2-hr monitoring of neoral on safety and efficacy outcomes in de novo cardiac transplant recipients receiving basiliximab induction: 6-Month results.
Cantarovich, M
Ross, H
Arizon, JM
Gomez, MA
Straatman, L
Orus, J
Alonso-Pulpon, L
Molina, BD
Wang, S
Lage, E
Crespo, MG
Manito, N
Howlett, J
Haddad, H
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 249 - 249
[5] Efficacy and Safety of Low-Dose Transdermal Buprenorphine Patches (5, 10, and 20 μg/h) Versus Prolonged-Release Tramadol Tablets (75, 100, 150, and 200 mg) in Patients With Chronic Osteoarthritis Pain: A 12-Week, Randomized, Open-Label, Controlled, Parallel-Group Noninferiority Study
Karlsson, Mats
Berggren, Anna-Carin
CLINICAL THERAPEUTICS, 2009, 31 (03) : 503 - 513

← 1 →